Validea Joel Greenblatt Daily Strategy Update Report – 09/11/2021


THere are today’s updates for Validea Profit Yield Investor model based on the published strategy of Joel greenblatt. This value model seeks companies with high return on capital and high profits.

CITI TRENDS, INC. (CTRN) is a small cap value stock in the retail sector (clothing). The rating according to our strategy based on Joel Greenblatt has increased from 70% to 80% depending on the underlying fundamentals of the company and the valuation of the stock. A score of 80% or more usually indicates that the strategy has some interest in the stock and a score above 90% generally indicates a strong interest.

Business Description: Citi Trends, Inc. is a specialty retailer of home clothing, accessories and trends, primarily for African American and Latin families. The Company operates approximately 584 stores in urban, suburban and rural markets in 33 states. It offers a range of products including clothing for juniors and women (plus size), including fashion sportswear, outerwear, sleepwear, lingerie and scrubs. It offers men’s clothing, including sportswear and outerwear; fashion clothes for boys and girls up to size 20 and sizes for newborns, infants and toddlers, as well as children’s uniforms and accessories. The Company also provides fashionable handbags, luggage, hats, belts, sunglasses, jewelry and watches for men and women, as well as basic underwear and beauty deals and perfumes for women and men; casual and dress shoes in sizes for men, women and children; household items for the bedroom, bathroom, kitchen and decorative accessories.

The following table summarizes whether the title meets each of the tests for this strategy. Not all of the criteria in the table below are given the same weight or are independent, but the table gives a brief overview of the strengths and weaknesses of the title in the context of the strategy criteria.

BENEFICIARY RETURN: NEUTRAL
RETURN ON BODILY CAPITAL: NEUTRAL
FINAL CLASSIFICATION: TO FAIL

Detailed analysis of CITI TRENDS, INC.

Full Guru Analysis for CTRN

Full Factor Report for CTRN

EMERGENT BIOSOLUTIONS INC (EBS) is a mid-cap value equity in the biotechnology and drugs sector. The rating according to our strategy based on Joel Greenblatt has increased from 70% to 80% depending on the underlying fundamentals of the company and the valuation of the stock. A score of 80% or more usually indicates that the strategy has some interest in the stock and a score above 90% generally indicates a strong interest.

Company Description: Emergent BioSolutions Inc. is a company specializing in the life sciences. The Company is focused on protecting and improving life by providing specialized products to civilian and military populations that respond to accidental, intentional and naturally emerging public health threats. It focuses on the development, manufacture and commercialization of medical countermeasures that address public health threats (PHT). PHT operates across two categories: chemical, biological, radiological and nuclear, as well as explosives threats and emerging infectious diseases. It operates through four business units: Vaccines and Anti-infectives; Therapeutic antibodies; Devices and contract manufacturing. The Vaccines and Anti-Infections business unit consists of BioThrax, which is intended for general use prophylaxis and post-exposure prophylaxis for anthrax. The Devices business unit includes marketed products such as Reactive Skin Decontamination Lotion Kit (RSDL) and Trobigard (Atropine Sulfate, Obidoxime Chloride).

The following table summarizes whether the title meets each of the tests for this strategy. Not all of the criteria in the table below are given the same weight or are independent, but the table gives a brief overview of the strengths and weaknesses of the title in the context of the strategy criteria.

BENEFICIARY RETURN: NEUTRAL
RETURN ON BODILY CAPITAL: NEUTRAL
FINAL CLASSIFICATION: TO FAIL

Detailed analysis of EMERGENT BIOSOLUTIONS INC

Full Guru Analysis for EBS

Full Factor Report for EBS

More details on Validea’s Joel Greenblatt strategy

Joel Greenblatt Ideas for action

About Joel Greenblatt: In his 2005 bestseller, The Little Book That Beats The Market, hedge fund manager Joel Greenblatt presented a surprisingly simple way to beat the market using two – and only two – fundamental variables. The “magic formula,” as he called it, produced post-tested returns of 30.8% per annum from 1988 to 2004, more than doubling the 12.4% return of the S&P 500 during that time. Greenblatt also produced exceptional returns as a managing partner of Gotham Capital, a New York-based hedge fund he founded. The company has averaged a remarkable 40% annualized return over more than two decades.

About Validea: Validea is an investment research service that tracks strategies published by investment legends. Validea offers both equity analysis and model portfolios based on gurus who have outperformed the market over the long term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information on Validea, Click here

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


Source link

Previous On the persistence of the Chinese shock
Next 54th Raymond Frye Memorial Horseshoe Tournament Today at Jim Barnett Park | Winchester Star